Last €32.22 EUR
Change Today -0.125 / -0.39%
Volume 0.0
OLY1 On Other Exchanges
As of 2:15 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

olympus corp (OLY1) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/15 - €33.28
52 Week Low
04/15/14 - €20.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OLYMPUS CORP (OLY1)

Related News

No related news articles were found.

olympus corp (OLY1) Related Businessweek News

View More BusinessWeek News

olympus corp (OLY1) Details

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates in four segments: Medical Business, Scientific Solutions Business, Imaging Business, and Others Business. The Medical Business segment provides endoscopy systems comprising videoscopes, video processors, light sources, and liquid crystal display panels; peripheral equipment, such as image recording devices, endoscope cleaning systems, sterilization systems, etc.; surgical video endoscopy systems, peripheral devices for endoscopic surgery, electrosurgical knives, etc.; and endoscopic devices for various diagnostic and treatment procedures, including biopsy forceps, high-frequency polypectomy snares, grasping forceps, stone retrieval and lithotriptor baskets, hemostasis accessories, etc. The Scientific Solutions Business segment offers upright and polarizing microscopes, inverted microscopes, laser confocal microscopes, box-type fluorescence imaging devices, stereo microscopes, fluorescence macro microscopes, microscope digital cameras, imaging software, bio-imaging systems, and virtual slide systems; and metallurgical microscopes, semiconductor inspection microscopes, laser and measuring microscopes, microscopic 3D measurement systems, industrial videoscopes and fiberscopes, industrial rigid scopes, ultrasonic flaw detectors, eddy current flaw detectors, phased array flaw detectors, X-ray diffraction analyzers, and peripheral equipment. The Imaging Business segment offers digital single-lens cameras, compact digital cameras and related products, digital camera lens barrels, and optical components, as well as IC recorders and binoculars. The Others Business segment manufactures biomedical materials, as well as conducts system development and other business activities. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.

30,702 Employees
Last Reported Date: 06/26/14
Founded in 1919

olympus corp (OLY1) Top Compensated Officers

President and Representative Director
Total Annual Compensation: ¥100.0M
Compensation as of Fiscal Year 2014.

olympus corp (OLY1) Key Developments

Olympus Introduces its New Dual Linear Array Probe for Fast, Simple, and Reliable Corrosion Imaging

Olympus announced the introduction of its new Dual Linear Array probe designed to improve the inspection of internally corroded parts such as pipes, tanks, and plates. The new Dual Linear Array probe provides the inspector with several advantages over conventional ultrasonic dual element transducers that are typically used with flaw detectors. This phased array solution improves productivity through features such as larger beam coverage, faster scan speed and C-scan imaging with increased data-point density. The pitch-catch technique used by this new probe offers better near-surface resolution and pit detection in corrosion survey applications than standard phased array pulse-echo, improving probability of detection of critical wall thinning. Its compact, lightweight aluminum housing provides easy handling and operation while carbide wear plates protect the wedges for increased durability. The Dual Linear Array probe adds a new low-cost entry-level inspection capability to the existing Olympus HydroFORM and RexoFORM corrosion solutions, especially when combined with the OmniScan SX. When using the probe with an OmniScan phased array instrument, the setup and operation is simple: load the setup file, check the calibration, and then inspect and record the data. The Dual Linear Array probe adds a new low-cost entry-level inspection capability to the existing Olympus HydroFORM and RexoFORM corrosion solutions. This new probe is yet another product in Olympus’ complete offerings for corrosion inspection solutions utilizing ultrasound, phased array, eddy current, and remote visual inspection.

Olympus Corporation Releases Two New Systems in Fluoview Series

Olympus Corporation has announced that its scientific solutions business has released two new systems of its Fluoview FVMPE-RS multi photon laser scanning microscope, a gantry microscope system and an inverted microscope system. Olympus markets its biological confocal laser scanning microscopes and multi photon laser scanning microscopes for use in life science research as the FLUOVIEW series. An appreciated feature of the series is its ability to capture 3D images with high contrast by detecting the very weak light (fluorescence) produced by samples when scanned with a laser beam. The series includes the FLUOVIEW FVMPE-RS multi photon laser scanning microscope (released in July 2013), the high-end model among Olympus's biological microscopes, which can capture rapid biological responses at deep sites. Adding to the existing upright microscope system, Olympus has now released gantry and inverted systems. By providing a range of three microscope systems from which to choose the variant best suited to the samples to be observed, this further enhances the scope for the FLUOVIEW FVMPE-RS to contribute to leading edge research by opening up a wider range of observation possibilities. Positioned as the high-end model in Olympus's range of biological microscopes, and used in life science research, the FLUOVIEW FVMPE-RS features faster scanning speed and more enhanced performance at deep observation than other models in the FLUOVIEW series. In addition to using the high speed scanner to observe rapid biological responses, the FLUOVIEW FVMPE-RS can also obtain vivid images from as deep as 8mm below the surface of tissue. Considerable space is available beneath the objective to allow the observation of samples of many different sizes. A volume 640 mm wide, 355 mm high, and 520 mm deep is available if the stage is removed, providing the system with sufficient space for the researcher's own experimental apparatus and giving it the flexibility to suit different observation purposes.

Olympus Corporation Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014; Provides Earnings Guidance for the Year Ending March 31, 2015

Olympus Corporation reported consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the nine months, the company reported net sales of JPY 550,015 million against JPY 513,674 million a year ago. Operating income was JPY 62,068 million against JPY 49,896 million a year ago. Ordinary income was JPY 48,203 million against JPY 34,116 million a year ago. Net income was JPY 31,926 million or JPY 93.27 per share diluted against JPY 5,843 million or JPY 17.78 per share diluted a year ago. Income before provision for income taxes was JPY 40,750 million against JPY 15,132 million a year ago. Capital expenditure was JPY 27,786 million against JPY 26,256 million a year ago. EBITDA was JPY 38,522 million against JPY 83,036 million a year ago. Cash flow from operating activities was JPY 35,759 million against JPY 43,805 million a year ago. Free cash flow was JPY 14,247 million against JPY 29,905 million a year ago. Net interest-bearing debt declined JPY 13.1 billion to JPY 150.6 billion as at December 31, 2014. For the third quarter, the company reported net sales of JPY 195,002 million against JPY 179,844 million a year ago. Operating income was JPY 23,642 million against JPY 21,393 million a year ago. Ordinary income was JPY 18,534 million against JPY 17,163 million a year ago. Net income was JPY 9,595 million or JPY 93.27 per share diluted against JPY 13,781 million or JPY 17.78 per share diluted a year ago. Income before income taxes and minority interest was JPY 12,815 million against JPY 16,682 million a year ago. Capital expenditure was JPY 10,366 million against JPY 9,024 million a year ago. EBITDA was JPY 98,906 million against JPY 83,036 million a year ago. Cash flow from operating activities was JPY 6,190 million against JPY 14,392 million a year ago. Free cash out flow was JPY 1,067 million against free cash inflow of JPY 11,205 million a year ago. For the full year ending March 31, 2015, the company expects net sales of JPY 760,000 million, operating income of JPY 88,000 million, ordinary income of JPY 70,000 million, net income of JPY 45,000 million, net income per share of JPY 131.49, capital expenditure of JPY 44,000 million, depreciation and amortization of JPY 39,000 million and EBITDA of JPY 136,500 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OLY1:GR €32.22 EUR -0.125

OLY1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avery Dennison Corp $54.30 USD -0.13
Boston Scientific Corp $16.82 USD -0.10
Hoya Corp ¥4,828 JPY -22.50
Nikon Corp ¥1,545 JPY +5.00
Smith & Nephew PLC 1,187 GBp +6.00
View Industry Companies

Industry Analysis


Industry Average

Valuation OLY1 Industry Range
Price/Earnings 38.2x
Price/Sales 2.0x
Price/Book 3.6x
Price/Cash Flow 20.2x
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OLYMPUS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at